NCT07205081Befejeződött1. fázis
Safety, Tolerability and PK of ATTO-3712 in Healthy Volunteers and Patients With Atopic Dermatitis
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multi-Part, Single Ascending Dose and Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of ATTO-3712 in Healthy Adult Volunteers and Patients With Atopic Dermatitis
Forrás: ClinicalTrials.gov · Utoljára frissítve: 2026. szept. 11.
Rövid összefoglaló (regiszter, angolul)
The goal of this clinical trial is to assess the safety, tolerability, and pharmacokinetics of ATTO-3712 in healthy adults and patients with atopic dermatitis. The main questions it aims to answer are: What medical problems do participants have when taking ATTO-3712? How long does ATTO-3712 stay in the body after dosing? Researchers will compare ATTO-3712 to a placebo (a look-alike substance that contains no drug). Participants will be dosed with ATTO-3712 or a placebo, visit the clinic for checkups and tests, and keep a diary of their symptoms.
- Állapot (regiszter)
- Befejeződött
- Fázis (regiszter)
- 1. fázis
- Vizsgálattípus
- Beavatkozással járó
- Résztvevők száma
- 48 (tényleges)
- Első benyújtás
- 2025. szept. 24.
- Kezdés
- 2025. okt. 22.
- Elsődleges befejezés
- 2026. aug. 13.
- Fő szponzor
- Attovia Therapeutics Inc
- Betegségek
- Atópiás dermatitisz (ekcéma)
- NCT-szám
- NCT07205081
Mit vállalsz
- Vizsgálat típusa: Beavatkozással járó · 1. fázis
- Bevont résztvevők: 48
- 2025. okt. 22. és az elsődleges befejezés (2026. aug. 13.) között
- 17 helyszín, 3 országban
- Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket
A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.
Ki nem vehet részt
Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.
A regiszterben nem jelölt feltételek
- Parts 1\&2 (Healthy Volunteers) Key Inclusion Criteria:
- Any sex or gender who is 18 to 65 years old, inclusive, at Screening.
- Body weight of 50 to 125 kg and body mass index (BMI) between 18.5 and 35 kg/m2
- Considered in good general health based on medical history, physical exam, 12-lead ECG, screening clinical laboratory findings, and vital signs
- Negative pregnancy test for participants of child-bearing potential.
- Part 3 (Participants with Atopic Dermatitis) Key Inclusion Criteria:
- Any sex or gender who is 18 to 65 years old
- Body weight of 50 to 125 kg and BMI between 18.5 and 40 kg/m2
- Clinically confirmed diagnosis of active AD
- History of inadequate response to treatment with topical medications
- Baseline weekly mean of daily PP-NRS ≥ 4 at Day 1.
- EASI score of ≥ 16 at Screening and Day 1
- vIGA-AD score of ≥ 3 at Screening and Day 1
- ≥10% of body surface area (BSA) affected by AD at Screening and Day 1
- Use of topical bland emollient (moisturizer) at least once daily for at least 5 of the 7 days immediately before Day 1 and agrees to continue using that same emollient at the same frequency throughout the study
- Negative pregnancy test for participants of childbearing potential
- Parts 1 \& 2 (Healthy Volunteers) Key Exclusion Criteria
- Any clinically significant underlying illness
- History of malignancy within 5 years of Screening
- History of major surgery within 8 weeks prior to Day 1 or has a major surgery planned during the study
- History of uncontrolled asthma requiring rescue treatment with a bronchodilator for an increase in symptoms more than twice per week
- History of hypersensitivity (including anaphylaxis) to a biologic medication, vaccine, an immunoglobulin product (plasma-derived or recombinant, eg, monoclonal antibody), or to any of the IP excipients (sucrose, polysorbate 80, or histidine)
- Active hepatitis B virus (HBV) or hepatitis C virus (HCV) or is positive for HIV
- Active or latent tuberculosis infection
- Smoking more than 20 cigarettes (or cigars, cigarillos, or e-cigarettes equivalent) per day
- History of drug or alcohol abuse
- Laboratory values outside of the normal range
- Part 3 (Participants with Atopic Dermatitis) Key Exclusion Criteria:
- Any clinically significant underlying illness
- Presence of skin comorbidities that may interfere with study assessments
- Has taken prescription medication for the treatment of AD or other prohibited medication within the restricted time limits (defined in the protocol)
- Has applied topical corticosteroids within 2 weeks prior to dosing.
- History of malignancy within 5 years of Screening
- History of major surgery within 8 weeks prior to Day 1 or has a major surgery planned during the study
- History of uncontrolled asthma requiring rescue treatment with a bronchodilator for an increase in symptoms more than twice per week
- History of recurrent eczema herpeticum
- History of known primary immunodeficiency, is considered immunocompromised, history of untreated latent tuberculosis infection, has been treated for active tuberculosis in the past year, or has been treated for a parasitic infection in the past 6 months
- History of major depression
- History of hypersensitivity (including anaphylaxis) to a biologic medication, vaccine, an immunoglobulin product (plasma-derived or recombinant, eg, monoclonal antibody), or to any of the IP excipients (sucrose, polysorbate 80, or histidine)
- Participant has experienced significant flare(s) in AD in the 2 weeks prior to Screening or during the Screening period
- EASI score for the participant has more than doubled between Screening and Day 1
- Active HBV or HCV or is positive for HIV
- Participant is smoking more than 20 cigarettes (or cigars, cigarillos, or e-cigarettes equivalent to approximately 40 mg nicotine) per day
- Participant has an ECG with a QTcF > 450 msec for males or > 470 msec for females at Screening
- History of drug or alcohol abuse
- Laboratory values outside of the normal range
Életkor a regiszterben: 18 év – 65 év · Nem: nők és férfiak · Egészséges önkénteseket is fogad
Helyszínek (17)
Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.
| Helyszín | Város | Ország | Helyszín állapota |
|---|---|---|---|
| Altasciences | Montreal | Kanada | Ismeretlen állapot |
| - | Peterborough | Kanada | Ismeretlen állapot |
| - | Auckland | Új-Zéland | Ismeretlen állapot |
| - | Auckland | Új-Zéland | Ismeretlen állapot |
| - | Christchurch | Új-Zéland | Ismeretlen állapot |
| - | Hamilton | Új-Zéland | Ismeretlen állapot |
| - | Nelson | Új-Zéland | Ismeretlen állapot |
| - | Wellington | Új-Zéland | Ismeretlen állapot |
| - | Coral Gables | Egyesült Államok | Ismeretlen állapot |
| - | Encinitas | Egyesült Államok | Ismeretlen állapot |
| - | Fountain Valley | Egyesült Államok | Ismeretlen állapot |
| - | Huntington Beach | Egyesült Államok | Ismeretlen állapot |
| - | Indianapolis | Egyesült Államok | Ismeretlen állapot |
| - | New York | Egyesült Államok | Ismeretlen állapot |
| - | Rocklin | Egyesült Államok | Ismeretlen állapot |
| - | Saint Joseph | Egyesült Államok | Ismeretlen állapot |
| - | Sweetwater | Egyesült Államok | Ismeretlen állapot |
Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.